Manufacturer of Controlled Substances Notice of Application, 10680 [05-4222]
Download as PDF
<![CDATA[
10680
Federal Register / Vol. 70, No. 42 / Friday, March 4, 2005 / Notices
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: February 23, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–4222 Filed 3–3–05; 8:45 am]
Dated: February 22, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–4203 Filed 3–3–05; 8:45 am]
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
Pursuant to 21 U.S.C. 958(1), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in Schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2)(b) authorizing the importation
of such substances, provide
manufacturers holding registrations for
the bulk manufacture of the substances
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on
December 9, 2004, Lipomed Inc., One
Broadway, Cambridge, Massachusetts
02142, made application by renewal to
the Drug Enforcement Administration
(DEA) for registration as an importer of
the basic classes of controlled
substances:
Drug Enforcement Administration
Importation of Controlled Substances;
Notice of Application
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances Notice of Application
Pursuant to 21 CFR 1301.33(a), Title
21 of the Code of Federal Regulations
(CFR), this is notice that on December
9, 2004, Lin Zhi International Inc., 687
North Pastoria Avenue, Sunnyvale,
California 94085, made application by
renewal to the Drug Enforcement
Administration (DEA) for registration as
a bulk manufacturer of the basic classes
of controlled substances listed in
Schedule II.
Drug
Schedule
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
II
II
The company plans to manufacture
the listed controlled substances in bulk
for use in analysis and drug test
standards.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a)
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than May 3, 2005.
VerDate jul<14>2003
19:07 Mar 03, 2005
Jkt 205001
BILLING CODE 4410–09–P
Drug
Schedule
Cathinone (1235) ..........................
Methaqualone (2565) ...................
Gamma-Hydroxybutyric
Acid
(2010).
Lysergic acid diethylamide (7315)
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
3,4,5-Trimethoxyamphetamine
(7390).
4-Bromo-2–5dimethoxyamphetamine (7391).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
2,5-Dimethoxy-4ethylamphetamine (7399).
3,4-Methylenedioxyamphetamine
(7400).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4-Methylenedioxymethamphetamine (7405).
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
Acetyldihydrocodeine (9051) ........
Dihydromorphine (9145) ...............
Heroin (9200) ...............................
Tilidine (9750) ...............................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Secobarbital (2315) ......................
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
Drug
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Methadone (9250) ........................
Dextropropoxphene (9273) ..........
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Alfentanil (9737) ...........................
Fentanyl (9801) ............................
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import small
reference standard quantities of finished
commercial product from its sister
company in Switzerland for distribution
to its customers for drug testing and
pharmaceutical research and
development.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file written
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than April 4, 2005.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–43746), all applicants for
registration to import basic class of any
controlled substance in Schedule I or II
are and will continue to be required to
demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
E:\FR\FM\04MRN1.SGM
04MRN1
]]>Agencies
[Federal Register Volume 70, Number 42 (Friday, March 4, 2005)]
[Notices]
[Page 10680]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-4222]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances Notice of Application
Pursuant to 21 CFR 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on December 9, 2004, Lin Zhi
International Inc., 687 North Pastoria Avenue, Sunnyvale, California
94085, made application by renewal to the Drug Enforcement
Administration (DEA) for registration as a bulk manufacturer of the
basic classes of controlled substances listed in Schedule II.
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Oxycodone (9143)........................... II
Hydrocodone (9193)......................... II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for use in analysis and drug test standards.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a)
Any such written comments or objections being sent via regular mail
may be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Attention: DEA Federal Register
Representative, Liaison and Policy Section (ODL); or any being sent via
express mail should be sent to DEA Headquarters, Attention: DEA Federal
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria,
Virginia 22301; and must be filed no later than May 3, 2005.
Dated: February 23, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 05-4222 Filed 3-3-05; 8:45 am]
BILLING CODE 4410-09-P
